Pharmacogenomic profiling prevents highly lethal chemotherapy overdoses in pediatric leukemia

Why a standard dose can be unsafe

Chemotherapy doses are often chosen for a typical patient, but the body’s ability to handle a drug can vary. Some medicines are broken down or inactivated by enzymes—proteins that help chemical reactions happen. If a child inherits a version of an enzyme that works less efficiently, a usual dose may remain active longer or build up to a higher level than expected.

In leukemia treatment, this matters for thiopurine drugs such as mercaptopurine, which may be taken over an extended period. Too much active drug can injure the bone marrow, the tissue that makes blood cells. Severe marrow suppression can leave a child dangerously short of infection-fighting white cells and other blood cells, interrupting treatment and sometimes requiring urgent care.

Genes can guide the starting dose

Pharmacogenomic testing looks for inherited differences in genes that affect how a person responds to medicines. For thiopurines, variants in genes such as TPMT and NUDT15 can signal that a child is more vulnerable to toxicity at standard doses. A clinician can use that information to begin with a lower dose and adjust it carefully rather than waiting for serious side effects to reveal that the dose is too high.

The result is a dosing clue, not a complete forecast. A genetic test does not capture every cause of toxicity, and children without the flagged variants still need routine blood tests and dose adjustments. Other medicines, illness, and changes in a child’s condition can also affect treatment.

Safer dosing without abandoning treatment

The goal is not simply to give less chemotherapy. It is to find a dose the child can tolerate while keeping treatment effective. Blood counts and clinical monitoring help the care team see how the body is responding and refine the plan over time.

That makes genetic information especially useful before a long course begins: it can help clinicians avoid exposing a highly sensitive child to a dose likely to cause severe harm, while preserving room to tailor treatment for the individual.